PPARD and stroke disorder: PPARβ/δ agonists, acting through PPARβ/δ activation, induce protection in many pathological CNS states, such as a transgenic mouse model of Alzheimer’s disease, MPTP model of Parkinson’s disease, stroke, EAE, spinal cord injury and in a streptozotocin-induced experimental type 3 diabetes [100]; in all these cases, the effect has been mainly attributed to reduction of inflammation and oxidative stress.